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PREAMBLE
This procedural position paper on the use of
imaging in the management of patients with known or
suspected cardiac sarcoidosis has been developed under
the auspices of the Cardiovascular and the Inflammation
and Infection Committee of the European Association of
Nuclear Medicine, the European Association of Cardio-
vascular Imaging of the European Society of
Cardiology, and the American Society of Nuclear
Cardiology, highlighting the close collaboration
between the societies on this topic.
INTRODUCTION
Sarcoidosis is a multisystem inflammatory granu-
lomatous disease of unknown origin. Granulomas in
sarcoidosis are compact, centrally organized collections
of macrophages and epithelioid cells that are surrounded
by lymphocytes. Granulomas from sarcoidosis are most
often located in the lungs or its associated lymph nodes,
but any organ can be affected.
Sarcoidosis affects approximately 10 out of 100,000
persons each year.1 Cardiac sarcoidosis is reported to
involve only 2%-5% of patients with systemic sarcoido-
sis,2,3 even though autopsy studies indicate a
considerably greater prevalence of 27%.4,5 There is also
evidence indicating that sarcoidosis can be clinically
confined to the heart.6 Cardiac involvement may range
from silent myocardial granulomas to symptomatic
conduction disturbances, ventricular arrhythmias, pro-
gressive heart failure, and sudden death, accounting for
13%-25% of disease-related deaths.5 The clinical course
of cardiac sarcoidosis varies from benign to life-threat-
ening with severe heart failure and sudden cardiac
death.7 The management of cardiac sarcoidosis involves
both immunosuppressive therapy for the treatment of
sarcoidosis and cardiac-specific therapies to manage
ventricular dysfunction and device therapy (pacemaker/
ICD) for heart blocks and heart rhythm disturbances.
The decision for drug therapy alone or the implantation
of an ICD for primary prevention in the early stage of
cardiac sarcoidosis remains challenging. Nevertheless, it
is felt that early initiation of immunosuppressive therapy
may prevent progression of cardiac dysfunction and
improve clinical outcomes.8
To date, the diagnosis and long-term management
of cardiac involvement remain controversial. Cardiac
sarcoid granulomas affect the whole heart but in a focal
manner. Also, acutely inflamed epithelioid-cell granu-
lomas as well as chronic fibrotic stage granulomas, may
exist in different parts of the heart of any given patient.
Consequently, blind endomyocardial biopsy of the
right side of the interventricular septum has a low
diagnostic yield, 20%-30%, and it is unreliable to
assess whole heart burden of inflammation or fibrosis.
Molecular imaging of increased metabolic activity in
the granulomas using 18F-fluorodeoxyglucose (FDG)
positron emission tomography (PET) provides the
advantages of whole heart evaluation and the ability
to identify granulomas with active inflammation.
EACVI Reviewers:
This document was reviewed by members of the EACVI Scientific Documents Committee for 2014–2016 and
2016–2018:
Victoria Delgado Bernhard Gerber
Nuno Cardim Kristina Haugaa
Bernard Cosyns Massimo Lombardi
Frank Flachskampf Pier Giorgio Masci
This joint position paper illustrates the role and the correct use of echocardiography, radionuclide imaging with
18F-fluorodeoxyglucose positron emission tomography, radionuclide myocardial perfusion imaging, and cardio-
vascular magnetic resonance imaging for the evaluation and management of patients with known or suspected
cardiac sarcoidosis. This position paper will aid in standardizing imaging for cardiac sarcoidosis and may
facilitate clinical trials and pooling of multi-centre data on cardiac sarcoidosis. Proposed flow charts for the work
up and management of cardiac sarcoidosis are included.
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Cardiovascular magnetic resonance (CMR) on the
other hand is highly sensitive to detect fibrosis. The
Japanese Ministry of Health, Labour and Welfare
(JMHW) criteria have been widely used for the
diagnosis of cardiac sarcoidosis. But, they do not
include FDG-PET or CMR.9 The Heart Rhythm Soci-
ety (HRS) consensus document has included FDG-PET
and CMR in the diagnostic criteria for cardiac sar-
coidosis.10 However, procedural details of imaging are
not covered in that document.
The purpose of this joint procedural position paper
is to describe the role and the correct use of the different
imaging techniques including radionuclide imaging
[FDG-PET, radionuclide myocardial perfusion imaging
(MPI)], CMR, and echocardiography for the manage-
ment of patients with known or suspected cardiac
sarcoidosis. We further hope that this position paper will
aid in standardizing imaging for cardiac sarcoidosis with
conventional and novel imaging techniques and facili-
tate clinical studies and pooling of multi-center data on
cardiac sarcoidosis.
ROLE OF DIFFERENT IMAGING TECHNIQUES IN
CARDIAC SARCOIDOSIS
Echocardiography
Rationale. Echocardiography is widely available
and often provides the first suspicion for cardiac
sarcoidosis.
Image acquisition. Several traditional and
advanced echocardiographic approaches can be used
with standard acquisition and interpretation proto-
cols.11–18 Stress echocardiography has a limited role in
the diagnosis of cardiac sarcoidosis; it may be helpful to
exclude epicardial coronary artery disease as a cause of
left ventricular systolic dysfunction and focal regional
wall motion abnormalities.
Interpretation and reporting. Cardiac sar-
coidosis can manifest with normal function or with
dilated or restrictive cardiomyopathy.19–21 The ventricle
may be globally hypokinetic or the patchy nature of sarcoid
infiltration of the heart may result in regional wall motion
abnormalities in a non-coronary distribution. Mild wall
thickening may be present related to oedema or infiltration.
In some cases, the increase in myocardial wall thickness
([13 mm) can simulate LV hypertrophy. Increased ven-
tricular wall echogenicity (bright aspect), particularly the
ventricular septum or the LV free wall, is frequent; and can
reflect scar formation and granulomatous inflammation.
More commonly, areas of wall thinning are seen, especially
in the ventricular septum, probably as a result of scar. A
typical but uncommon finding is the thinning (\7 mm) and
akinesia of the basal septum, while the distal septum and
apex are contracting normally, and the presence of ven-
tricular aneurysm in the inferolateral wall20,22–24
(Figure 1). Echocardiographic features of cardiac sar-
coidosis echo can also mimic arrhythmogenic right
ventricular dysplasia/cardiomyopathy.25,26 In the early
stage of the disease, reduced longitudinal myocardial
function (2D speckle tracking or tissue Doppler imaging-
derived strain)27–32 or alterations in acoustic properties of
the myocardium,33,34 particularly in the basal interventric-
ular septum, may be present in the absence of other 2D echo
features. About 20% of patients with cardiac sarcoidosis
have atrial lesions characterized by atrial wall hypertrophy
(easier diagnosis by transoesophageal echocardiogra-
phy).35 On rare occasions, an appearance similar to
hypertrophic cardiomyopathy can be observed.36,37 Any
degree of diastolic dysfunction is a common but non-
specific finding.38 Small pericardial effusions, mitral, or
tricuspid regurgitation secondary to papillary muscle
dysfunction, pulmonary hypertension secondary to lung
implication, and/or ventricular dys-synchrony are other
echo parameters that can be potentially observed in cardiac
sarcoidosis. Tamponade and constrictive pericarditis have
been infrequently found.19 The right ventricular dilatation
and dysfunction at the end stage disease in cardiac
sarcoidosis as well as the predominance of basal septum
abnormalities in terms of contractility are important
findings on echocardiography.25
Diagnostic accuracy. Echocardiography can
detect cardiac structural abnormalities from cardiac
sarcoidosis. But in patients with extracardiac sarcoido-
sis, echocardiographic abnormalities are highly
variable, ranging from 4% to 55%, even without
clinical symptoms or ECG abnormalities.3,10 The mea-
surement of LV systolic and diastolic function and
evaluation of valvular disease severity are not specific
for sarcoidosis.39 Although newer techniques such as
Doppler, strain, and speckle tracking echocardiography
are useful in detecting abnormal myocardial function,
these imaging techniques cannot delineate tissue char-
acteristics and therefore cannot differentiate between
various types of cardiomyopathies.40 Using the criteria
of RV systolic dysfunction in the absence of pul-
monary hypertension, and/or significant diastolic
dysfunction inappropriate for the patient’s age,
echocardiography yields a sensitivity of 10%-47%
and a specificity of 82%-99% for the diagnosis of
cardiac sarcoidosis.10,41
In summary, standard 2D transthoracic echocardio-
graphy is a common initial test in patients with
suspected cardiac sarcoidosis. However, findings are
frequently non-specific for inflammation and not sensi-
tive for early changes from sarcoidosis. The primary role
of echocardiography in cardiac sarcoidosis, at this time,
is to assess and follow LV function.
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RADIONUCLIDE IMAGING
Radionuclide imaging with 67gallium-citrate SPECT
and FDG-PET have been used to diagnose myocardial
inflammation. 67Gallium-citrate is specific for inflam-
mation, but has relatively low sensitivity and poor spatial
resolution compared with FDG-PET, especially for
detecting extra-pulmonary sarcoidosis involvement.42
Therefore, the use of 67gallium-citrate SPECT to diag-
nose cardiac sarcoidosis is limited to centers without
access to FDG-PET. FDG-PET has emerged as a
powerful and most commonly used technique not only
to assess the extent of systemic sarcoidosis but also to
assess extent and activity of myocardial involvement.43
In addition, recent studies have demonstrated the impor-
tance of identifying perfusion defects in patients with
cardiac sarcoidosis, as this group of patients is at highest
risk for death or ventricular arrhythmias.44,45 FDG-PET
in conjunction with MPI is therefore the currently
recommended radionuclide method for evaluation of
cardiac sarcoidosis.
Figure 1. Example of echocardiography in cardiac sarcoidosis. Echocardiographic images
showing (A) a basal thinned basal septal wall (four-chamber view showing, arrows), (B–D)
aneurysmal dilatation involving inferior (B, D), and posterolateral (C) walls. (D) 3D image
displaying the inferior aneurysm (arrows).
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18F-Fluorodeoxyglucose Positron Emission
Tomography
Rationale. Active inflammatory cells have high
glycolytic activity to sustain their energy demands; the
accumulation of FDG in these activated macrophages
and CD4? T lymphocytes is the underlying mechanism
for in vivo visualization of active granulomatous sarcoid
lesions in various organs.46 Low carbohydrate diet and
prolonged fasting of the subject are recommend to
suppress myocardial FDG uptake to facilitate visualizing
FDG uptake in these inflammatory cells of cardiac
sarcoidosis. The role of FDG-PET for the diagnosis of
extracardiac sarcoidosis is well established; in contrast,
its role in cardiac sarcoidosis management and therapy
is currently under active investigation.
Patient preparation and image acquisi-
tion. Metabolic imaging to identify the non-caseating
granulomas of cardiac sarcoidosis takes advantage of
enhanced FDG uptake based on the high glycolytic
activity of inflammatory cells.47,48 However, the sur-
rounding normal myocardium can also use glucose as an
energy substrate, and therefore, it is important to
minimize physiological myocardial glucose utilization
to optimize the target to background ratio of FDG-PET
for identifying active cardiac sarcoid lesions. Patient
preparation for cardiac FDG-PET imaging for sarcoido-
sis is based on increasing the provision of fatty acids to
the heart and decreasing physiological uptake of glucose
by the myocardium.103 The current SNMMI/American
Society of Nuclear Cardiology (ASNC)/SCCT guideli-
nes recommend preparation with a fat-enriched diet
lacking carbohydrates for 12-24 hours prior to the scan,
a 12-18 hours fast, and/or the use of intravenous
unfractionated heparin approximately 15 minutes prior
to 18F-FDG injection.49 Careful patient preparation is
critical to optimize FDG-PET image quality. Details of
patient preparation are listed in Supplementary data
online, Supplement 1a and 1b.
The FDG-PET imaging protocol involves cardiac
image acquisition 90 minutes (minimum of 60 minutes)
after intravenous injection of 2.5-5 MBqkg-1 of
FDG50–52 (Table 1). Following FDG injection and
before the images are obtained, the patient should
continue to fast and should not be physically active, as
either of these will enhance myocardial glucose uptake.
In addition, limited whole body FDG imaging is
recommended to allow for the assessment of extracar-
diac disease activity (lung, lymph nodes, liver, spleen,
kidneys, and bones) and identify potential sites amen-
able for biopsy. Imaging procedures, including dietary
preparation and image acquisition parameters should be
documented and standardized on repeat studies, to
enable reliable quantitation and comparison of changes.
Exercise and/or myocardial ischemia can enhance
myocardial FDG uptake. For this reason, stress testing
should be avoided and patients should be advised not to
exert themselves on the day of cardiac sarcoid FDG
imaging. Also, note that patients with systolic LV
dysfunction may have increased glucose uptake due to
metabolic changes, which is likely diffuse rather than
focal.
Interpretation and reporting. Interpretation
of FDG-PET for cardiac sarcoidosis requires an under-
standing of the metabolic preparations necessary to
differentiate the pathological glucose uptake that is the
hallmark of sarcoidosis-related inflammation from phys-
iological myocardial glucose uptake. It is also important
to note that none of the interpretive strategies described
below have been validated experimentally, due to the
lack of a gold standard, and there is little data available
on comparing the various methods. The most common
method of interpreting FDG-PET for the evaluation of
cardiac sarcoidosis relies on the use of traditional
nuclear cardiology display systems as well as nuclear
medicine display systems.53 Typically short-axis, hori-
zontal, and vertical long-axis images of the FDG and
rest MPI are displayed together with the image intensity
normalized to the maximum counts per pixel of the
respective data set. These normalized images are
reviewed for four imaging patterns54:
1. No FDG uptake (‘none’),
2. Diffuse FDG uptake (‘diffuse’),
3. Focal FDG uptake (‘focal’),
4. Focal on diffuse FDG uptake (‘focal on diffuse’).
The presence of ‘focal’ or ‘focal on diffuse’ FDG
uptake is abnormal and may be consistent with cardiac
inflammation from sarcoidosis, while interpretation of
diffuse uptake is challenging as it can be non-specific
(possibly related to poor suppression of normal myocar-
dial glucose uptake) or may represent multiple sarcoid
granulomas with heterogeneous FDG uptake in a diffuse
distribution. The normal FDG image pattern for an
appropriately prepared patient is no myocardial FDG
uptake where the LV blood pool is brighter than the
myocardium, although low intensity FDG uptake in the
lateral wall is also often considered a normal finding,
particularly when such uptake is homogenous in inten-
sity and is not associated with any resting perfusion
defects.54 In addition to evaluating for abnormal FDG
uptake in the LV, it is also important to evaluate for
areas of focal FDG uptake in the right ventricle, which
may be associated with a worse prognosis.45 Lastly, the
use of FDG-PET combined with MPI will be particu-
larly helpful to judge the orientation of the image when
only focal FDG uptake is present.
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Table 1. Procedure guidelines for radionuclide myocardial perfusion and FDG imaging for cardiac
sarcoidosis
Imaging sequence
Myocardial perfusion imaging and FDG-PET at baseline
StandardMyocardial perfusion imaging and FDG-PET at follow-up
Myocardial perfusion
imaging
Preparation None Standard
Preparation for FDG-PET, if performed on the same day
Technique PET or SPECT Standard
Perfusion radiotracers 99mTc-sestamibi/tetrofosmin, 201Tl, 13N-ammonia, 82Rb Standard
Protocols Standard radiotracer dose and rest MPI protocols as per ASNC, EANM,
ESC
Standard
Attenuation correction when available Standard
Gated SPECT/PET MPI Standard
Review Review MPI along with FDG-PET
FDG-PET imaging
Preparation Dietary preparation to minimize physiological myocardial glucose
utilization
Standard
Type of PET scan Hybrid PET/CT Standard
Dedicated PET Acceptable
CT scan Low dose chest CT scan for attenuation correction without iodinated
contrast
Standard
Imaging mode 3D Standard
2D Acceptable
Dose 2.5–5 MBqkg-1 for 3D mode or Acceptable
5–10 mCi for 3D imaging and 10–20 mCi for 2D imaging Acceptable
FDG uptake period after
injection
90 minute Standard
60 minute Minimum
Scan field of view Dedicated cardiac scan and whole body to include neck through pelvis at
baseline
Standard
Dedicated cardiac scan and whole body to include neck through pelvis at
follow-up
Standard
Scan duration 10 minute for 3D cardiac PET Standard
20 minute for 2D cardiac PET Standard
3 minute per bed position partial whole body PET Standard
Scan type Static FDG-PET Standard
Gated FDG-PET Optional
Scan reconstruction Iterative reconstruction (OSEM) Standard
Attenuation correction Standard
With and without attenuation correction for hybrid PET/CT in individuals
with intracardiac devices
Standard
Scan interpretation Visual using cardiac imaging planes Standard
Whole body imaging using SUV scale Standard
Myocardial SUVmax Standard
Volume of myocardium above specific SUV threshold Standard
Interpretation by physicians experienced in nuclear cardiology, CT and
FDG imaging
Standard
Special considerations In individuals with recent intracardiac device placement or ablation wait 4–
6 weeks for FDG-PET
Optional
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The use of traditional nuclear cardiology display
systems to interpret relative FDG-PET images for
cardiac sarcoidosis has two limitations. First, since
these display schemes normalize image intensity to the
most intense pixel, it is difficult to judge the absolute
intensity of myocardial FDG uptake. This may be
important for understanding the severity of myocardial
inflammation and for evaluating the response to treat-
ment, particularly if only the intensity but not the
distribution of FDG uptake changes between studies.
Secondly, the issue of normalization is especially
important when the FDG signal is only mildly increased
above background. This can falsely cause these areas of
low absolute uptake to appear artificially intense in the
normalized display.
A review of the images for non-inflammatory
pathological FDG activity (cancer, other infections,
etc.) is accomplished using limited whole body
hybrid PET/CT. Hybrid FDG-PET/CT imaging, how-
ever, may be problematic in individuals with
intracardiac devices due to apparent focal increase
in FDG uptake at the site of lead insertion related to
errors from CT-based attenuation correction and/or
focal inflammation. In individuals with intracardiac
devices and suspected cardiac sarcoidosis, the non-
attenuation corrected FDG images could be reviewed
to overcome this limitation.
In addition to a visual review of the relative scaled
FDG images and hybrid PET-CT images, FDG images
should be assessed using a semi-quantitative scale and
standardized uptake values (SUVs). SUVs are defined as
the radioactivity concentration in the region of interest
in BqmL-1/(injected dose in Bqpatient weight in
g-1).55 Various metrics for quantification of FDG uptake
in cardiac sarcoidosis have been reported, including the
maximal SUV values in the heart (SUVmax),
45,55 the
total SUV value of the heart,55 mean SUV of the heart,56
heart-to-blood pool SUV ratios,57 coefficient of variance
of SUVs,58 and the volume,59 and volume-activity44,59
of voxels with intensities of FDG SUVs above various
thresholds. While these methods have not been rigor-
ously compared head-to-head, there is data to suggest
that they perform better than visual assessment of
normalized images to assess treatment response.44,59,60
A standard FDG-PET for cardiac sarcoidosis is typically
reported in conjunction with rest MPI (see Supplemen-
tary data online, Supplement 2).
Myocardial perfusion imaging. Cardiac sar-
coidosis may alter coronary microcirculation leading to
myocardial perfusion defects. Myocardial perfusion
abnormalities, including reversible perfusion defects
with adenosine or dipyridamole, have been reported in
cardiac sarcoidosis.56,61,62 However, unlike with coro-
nary artery disease, perfusion abnormalities related to
sarcoid granulomas typically do not match with coro-
nary territories. In the chronic phase, when epithelioid-
cell granulomas have been replaced by fibrosis, perfu-
sion defects become irreversible and may be associated
with segmental motion abnormalities according to the
transmural extent of the fibrotic scar.
The evaluation of the diagnostic performance of
perfusion SPECT and perfusion PET in cardiac sar-
coidosis is very scarce and limited.54–56 The potential
additional value of myocardial blood flow quantification
by PET in the diagnosis and evaluation of cardiac
sarcoidosis remains to be investigated. Due to the
limited sensitivity and specificity of MPI alone, and due
to the fact that abnormal MPI alone cannot distinguish
scar from active sarcoidosis, MPI is currently used for
the evaluation of cardiac sarcoidosis only in conjunction
with FDG-PET.
When combined with FDG-PET, standard PET or
SPECT MPI protocols are recommended.63–66 PET MPI
has advantages over SPECT for the identification of
small perfusion defects, as seen in patients with cardiac
sarcoidosis. When SPECT imaging is used, attenuation
correction and gated imaging are recommended to avoid
interpreting segments with attenuation artifacts as seg-
ments of true mismatch.67 Perfusion and FDG
abnormalities associated with cardiac sarcoidosis are
not specific for inflammation or scar from sarcoidosis.
Consequently, it is mandatory to rule out alternative
diagnoses such as CAD before interpreting myocardial
perfusion images.
Combined assessment of perfusion and
inflammation. The combined assessment of perfu-
sion and inflammation, preferably in hybrid imaging
setting, is likely to provide additional information about
the status of cardiac sarcoidosis (scar or inflammation)
and risk from cardiac involvement (Figure 2). In this
section, we will only consider the assessment of inflam-
mation by FDG-PET/CT combined with MPI since
67gallium-citrate scintigraphy is no longer regarded as a
method of choice.
Perfusion defects in patients with cardiac sarcoido-
sis can represent areas of scar or inflammation, while
abnormal FDG uptake represents inflammation
(Table 2). FDG and MPI patterns have been described
as ‘early’ (only FDG-positive), ‘progressive inflamma-
tory’ (FDG-positive without major perfusion defects),
‘peak active’ (high SUV FDG uptake with small
perfusion defects), ‘progressive myocardial impairment’
(high SUV FDG uptake with large perfusion defects) or
‘fibrosis-predominant’ (FDG negative, but with perfu-
sion defects)55 (Figure 2B). Another staging system
utilizes a nomenclature analogous to the scadding
system for staging pulmonary sarcoidosis, specifically,
Stage 0 (normal FDG, normal perfusion), Stage 1 (FDG-
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Figure 2. (A) Example of FDG and myocardial perfusion PET in sarcoidosis. The whole body
hybrid FDG-PET/CT study (A) showed multiple foci of inflammation in the mediastinum, but no
active inflammation in the myocardium; hybrid imaging confirms regions of FDG uptake in the
mediastinal lymph nodes and not the myocardium. Assessment of systemic disease activity is an
advantage of FDG-PET compared with echocardiography or CMR. (B) Patterns of myocardial
perfusion imaging (MPI) and FDG imaging of myocardial inflammation. This figure shows rest
MPI in the top row and FDG imaging of myocardial inflammation in the bottom row. A pattern of
no myocardial FDG uptake is normal if MPI is normal (A), or fibrosis when MPI is abnormal (F, the
pattern of FDG uptake represents blood pool activity). A pattern of diffuse myocardial FDG uptake
represents a non-specific finding that may be seen with incomplete suppression of physiological
myocardial glucose utilization and is not diagnostic for cardiac sarcoidosis (B). A pattern of focal
myocardial FDG uptake is consistent with active myocardial inflammation without (C, D, no
perfusion defect) or with coexistent fibrosis (E, perfusion defect). Of note, pattern (C), isolated
focal FDG uptake in the basal lateral wall in the absence of a perfusion defect, abnormal wall
motion, or delayed enhancement on CMR may have reduced specificity for active myocardial
inflammation.
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positive, normal perfusion), Stage 2 (FDG-positive with
perfusion defects in the same myocardial segments),
Stage 3 (FDG-positive with perfusion defects in differ-
ent segments), or Stage 4 (normal FDG, but perfusion
defects).68
Notably, the pattern of perfusion and inflammation
abnormalities in relation to the disease status is not
validated histologically or by outcomes. However, this
relationship may be important both for diagnosis, and
for the determination of prognosis and establishing
treatment,44,45,55 see next sections. It is noteworthy that
both resting perfusion defects as well as increased FDG
uptake may be caused by inflammation as well as
associated microvascular compression and local ische-
mia; for this reason, some perfusion defects may
actually improve following immunosuppressive therapy.
Diagnostic accuracy. FDG-PET is an accurate
tool for the detection of cardiac involvement in sar-
coidosis. Several studies reported on the sensitivity and
specificity of FDG-PET to detect cardiac sarcoidosis.1
These studies have included patients with and without
endomyocardial biopsy-proven cardiac involvement.
However, as with the data from the other imaging
methods, most of these studies were observational in
nature, included small sample size, lacked an adequate
reference standard, were limited by referral bias, and
used different protocols.
The sensitivity of FDG-PET for detecting cardiac
sarcoid is 85%-100% for most studies while the speci-
ficity is more variable (39%-100%) using the JMHW
criteria as the gold standard (Table 3).53–55,57,69,70 A
recent meta-analysis of seven studies demonstrated an
overall sensitivity of 89% and a specificity of 78% for
FDG-PET.70 However, these estimates are biased as the
lower specificity of PET in some studies may reflect the
fact that this test is more sensitive for identifying cardiac
sarcoidosis than the JMHW criteria. Indeed, the require-
ment of histologically proven extracardiac sarcoidosis
by the JMHW criteria limits identification of isolated
cardiac sarcoidosis, whereby the disease is confined only
to the heart,71 particularly if endomyocardial biopsy is
negative. Likewise, the lower sensitivity of FDG-PET in
some studies may reflect the reduced specificity of the
JMHW criteria. Several studies have compared FDG-
PET, either alone or combined with PET MPI, to
67gallium imaging and have demonstrated improved
accuracy for detecting cardiac sarcoid.42,53,54,57,72
Despite the high diagnostic accuracy of FDG-PET, it
is currently not included in the most recent updated
(2006) diagnostic criteria of the JMHW, published by
the Japan Society of Sarcoidosis and Other Granuloma-
tous Disorders.9 The more recent HRS Consensus
Recommendations10 suggest that clinical diagnosis of
cardiac sarcoidosis is probable if there is histological
proof of extracardiac sarcoidosis and one or more
findings which include a pattern consistent with cardiac
sarcoidosis on imaging [including dedicated cardiac
PET, late gadolinium enhancement (LGE) on CMR,
positive 67gallium imaging], unexplained reduced left
ventricular ejection fraction (LVEF)\40%, unexplained
Table 2. Interpretation of combined rest perfusion and FDG imaging
Rest
perfusion FDG Interpretation
Normal perfusion and metabolism
Normal No uptake Negative for cardiac sarcoidosis
Normal Diffuse Diffuse (usually homogeneous) FDG most likely
due to suboptimal patient preparation
Normal Isolated lateral wall uptake May be a normal variant
Abnormal perfusion or metabolism
Normal Focal Could represent early disease
Defect No uptake Perfusion defect represents scar from sarcoidosis
or other etiology
Abnormal perfusion and metabolism
Defect Focal in area of perfusion defect Active inflammation with scar in the same location
Defect Focal on diffuse with focal in area of
perfusion defect
Active inflammation with scar in the same location
with either diffuse inflammation or suboptimal
preparation
Defect Focal in area of normal perfusion Presence of both scar and inflammation in different
segments of the myocardium
Adapted from Blankstein et al45
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sustained [spontaneous or induced ventricular tachycar-
dia (VT)], second degree atrio-ventricular (AV) heart
block (Type 2, also called Mobitz Type II) or third
degree heart block, steroid/immunosuppression respon-
sive cardiomyopathy or heart block, and other causes for
the cardiac manifestation(s) have been reasonably
excluded.
In summary, FDG-PET is the best clinically avail-
able tool for imaging myocardial inflammation. Careful
preparation to suppress physiological myocardial glu-
cose utilization is essential for FDG-PET imaging of
cardiac sarcoidosis. Combined assessment of perfusion
and inflammation is necessary to provide optimal
information for the diagnosis, risk assessment, and
management of cardiac sarcoidosis.
CARDIOVASCULAR MAGNETIC RESONANCE
Rationale
CMR can provide a wide range of potentially
unique information in inflammatory and infiltrative heart
disease. Specific CMR imaging sequences with charac-
teristic findings in cardiac sarcoidosis have been
reported. Although evidence from large-scale prospec-
tive clinical studies for the use of CMR in cardiac
sarcoidosis is lacking, several smaller studies have
demonstrated its potential to detect cardiac involvement
in sarcoidosis and predict adverse clinical outcome.
Image Acquisition
Patient preparation for CMR is detailed in Supple-
mentary data online, Supplement 3. Standardized
acquisition protocols are available for all modern
cardiac enabled MRI scanners73 and in suspected
cardiac sarcoidosis typically include low resolution
localizer images, cine imaging in multiple planes,
oedema sensitive (T2-weighted), and LGE imaging,
with parametric mapping as an emerging addition.
Images should be acquired with standardized methods73
and in standardized and reproducible imaging planes,
allowing reliable correlation between different compo-
nents of the study. T2 weighted images, most commonly
using short tau inversion-recovery (T2-STIR) methods,
are sensitive to the free water content of tissue and can
thus detect myocardial inflammation and oedema in
cardiac sarcoidosis74 (Table 4). T2-STIR methods suffer
from relatively low sensitivity, however, due to low
contrast to noise ratio and can also be affected by
artifacts from slow moving blood at the endocardial
surface. LGE imaging uses dual inversion saturation
recovery pulse sequences to delineate myocardial tissue
with expanded extracellular space as occurs in infiltra-
tion, scaring, or fibrosis. Granulomatous infiltration in
cardiac sarcoidosis can be sensitively detected with this
method as focal hyperenhancement.7,76–81 Cine CMR is
most commonly performed with steady state free pre-
cession (SSFP) methods, acquiring a stack of images
Table 3. Sensitivity and specificity of FDG-PET for detecting cardiac sarcoidosis
References Years Patients EMB Sensitivity Specificity Remarks
Yamagishi et al53 2003 17 0/17 100 n.a. Only patients with histologic
evidence of extracardiac
sarcoidosis were included
Okumura et al55 2004 22 3/22 100 90.9 Diagnosis JMHW
Ishimaru et al54 2005 62 0/62 100 81.5 Included 30 healthy controls and
32 patients with suspected
sarcoidosis. Diagnosis 28 out of
32 with histologic evidence of
extracardiac sarcoidosis
Nishiyama et al42 2006 18 0/18 100 100 Diagnosis JMHW
Ohira et al69 2008 21 2/21 87.5 38.5 Diagnosis JMHW
Langah et al57 2009 65 1/65 85 90 Diagnosis JMHW
Youssef et al70 2012 164 n.a. 89 78 Meta-analysis of seven studies
Diagnosis JMHW
Blankstein et al45 2014 118 13/118 42.1 79.7 Based on patients that had both
abnormal FDG and 82rubidium
PET studies
Diagnosis JMHW
EMB, endomyocardial biopsy
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Table 4. Recommended CMR protocol and analysis in sarcoidosis
Pulse sequence Imaging planes Analysis and tips
Morphology and
function
(1) Steady state free
precession (SSFP) cine
imaging
(i) Whole heart
coverage in LV
short-axis plane
from the mitral valve
to the apex
Use real time acquisition
in patients with poor
breath holding
Slice thickness 6–8 mm, with
2–4 mm interslice gaps to
equal 10 mm
(ii) Four-chamber
plane
Report regional and
global LV and RV
function as well as
aneurysms and other
morphological
abnormalities
Temporal resolution B45 ms
between phases
(iii) Vertical long-axis
plane
Parallel imaging as available (iv) LV outflow tract
(LVOT) plane
T2-weighted imaging (1) Black blood T2-weighted
STIR (short tau inversion
recovery)
Same planes as for
cine imaging (short-
and long-axis views)
Report presence of focal
signal enhancement
suggestive of oedema
(2) Bright blood T2-weighted
sequences
Beware slow flow
artifacts at endocardial
border in particular in
long-axis planes
(a) T2-prepared single-shot
SSFP sequence
(b) Turbo spin echo-steady
SSFP hybrid
Late gadolinium
enhancement
(1) 2D/3D segmented
inversion-recovery gradient
or SSFP pulse sequence
Same planes as for
cine imaging (short-
and long-axis views)
PSIR is less dependent on
correct TI
(2) Phase-sensitive inversion-
recovery (PSIR) pulse
sequence
Use single shot for
patients with irregular
heart rhythm, and/or
difficulty breath
holding
(3) Single-shot imaging (SSFP
readout)
Slice thickness same as for
cine imaging
Report presence of focal
hyperenhancement
In-plane resolution, *1.4–
1.8 mm
Consider using
thresholding methods
Inversion time to null normal
myocardium
Acquisition duration per R-R
interval below 200 ms, less
in the setting of tachycardia
Readout usually every other
heart beat unless tachycardia
or bradycardia
Images acquired during
diastolic stand-still
Acquired at least 10 minute
after gadolinium injection
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covering the entire heart in the left ventricular short-axis
and additional long-axis sections. Cine CMR is the most
accurate imaging method for the measurement of left
and right heart dimensions and contractile function. In
later stages of cardiac sarcoidosis, contractile function
can be impaired and is sensitively detected and followed
up with CMR. Cine CMR also allows detection of
ventricular aneurysms, pericardial effusion, and valve
pathology. Increasingly, parametric T1 and T2 mapping
provide quantitative measures of tissue inflammation,
oedema, and diffuse fibrosis, but are only beginning to
be used in sarcoidosis, so that, experience with these
newer methods is limited.
Interpretation and Reporting
The most commonly found CMR abnormality in
patients with sarcoidosis is focal hyperenhancement on
LGE images, usually readily detectable by visual
inspection. Mid-wall or sub-epicardial enhancement in
the basal ventricular wall, the lateral wall, and septum is
considered the most common pattern in cardiac sar-
coidosis, but subendocardial or transmural enhancement
in other myocardial locations has also been described82
(Figure 3). Importantly, LGE findings are not specific to
sarcoidosis and the differential diagnosis from
myocarditis and other inflammatory conditions can be
Figure 3. Example of cardiac sarcoidosis diagnosed with
CMR. Late gadolinium enhanced CMR image from an Afro-
Caribbean male who presented with pulmonary sarcoidosis and
suspected cardiac involvement. The image shows focal mid-
myocardial contrast enhancement in the basal inferior and
lateral wall and septum (image courtesy Dr. Tevfik Ismail,
King’s College London, UK).
Table 4 continued
Pulse sequence Imaging planes Analysis and tips
T2 mapping (optional) (1) T2-prepared single-shot
SSFP sequence acquired with
different T2 prep time
Typically LV short-axis Acquire prior to contrast
administration
Review maps for
presence of focal signal
enhancement
suggestive of oedema
T1 mapping (optional) (1) Look locker imaging
(MOLLI or ShMOLLI or
equivalent)
Typically LV short-axis Performed prior to
contrast and at 2–4
time points post-
contrast bolus(2) Saturation recovery single-
shot acquisition (SASHA) Alternatively, constant
infusion of contrast can
be used rather than
bolus
Review maps for
presence of focal signal
enhancement
suggestive of
oedema/fibrosis
Modified from Kramer et al75
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challenging. Using thresholding methods, the extent of
hyperenhancement on LGE can be quantified to give a
measure of disease extent, but no consensus exists so far
to the optimal threshold for diagnosis. Oedema sensitive
images may show areas of high signal in patients with
cardiac sarcoidosis, suggestive of inflammation, and
oedema. However, reliable detection of oedema can be
difficult as T2 weighted images have a relatively low
signal to noise ratio and can be prone to artifacts, in
particular from slow flow at the endocardial boundary. A
careful review of the images is therefore mandatory. By
calculating the ratio of signal in skeletal muscle and the
myocardium, a semi-quantitative measure of oedema
can be derived. In sarcoidosis, cine CMR provides
quantitative measurements of volumes and EF and
shows similar abnormalities as seen on 2D echocardio-
graphy. A CMR report in suspected sarcoidosis should
include a description of extracardiac findings (including
lung nodules, splenic or hepatic perfusion defects),
measurements of right and left ventricular size, volumes,
and function, comments on pericardial and valve
pathology, presence of oedema, and a description of
the location and size of lesions seen on LGE.
Diagnostic Accuracy
Multi-parametric CMR is a sensitive tool for the
detection of cardiac involvement in sarcoidosis. How-
ever, to date CMR has only been used in relatively small
observational studies and as for other imaging modal-
ities, prospectively designed diagnostic accuracy studies
against histological endpoints are lacking. Similar to
FDG-PET studies, estimates of the diagnostic accuracy
of CMR in cardiac sarcoidosis are hampered by the lack
of a gold standard.
The first report on the diagnostic accuracy of CMR
for cardiac sarcoidosis showed a sensitivity of 100% and
specificity of 78% vs the JMHW criteria.80 The rela-
tively low specificity can be explained, as the CMR data
were compared using the low diagnostic sensitive
JMHW criteria. Patel et al, showed that CMR compared
with the JMHW criteria resulted in a higher incidence of
cardiac involvement in sarcoidosis (i.e., [2-fold
increase in cardiac sarcoidosis diagnosis vs JMHW
criteria), leading to a significant improvement in prog-
nostication of adverse events by CMR when compared
with JMHW criteria.82
The most consistently reported finding on CMR is
focal LGE, described in numerous smaller reports7,77–81
and two larger studies, which found LGE in 39 of 155
(25.5%) and 41 of 205 (20%) patients with extracardiac
sarcoidosis,76,83 and a systematic review and meta-
analysis.84 Importantly, LGE was seen in patients who
did not meet standard JMHW guidelines, suggesting that
CMR is a more sensitive test to detect cardiac involve-
ment in sarcoidosis than established diagnostic criteria,
however, specificity may be variable. Although small
reports have suggested that some lesions on LGE regress
following steroid therapy,85 this needs to be further
evaluated.
Oedema sensitive T2 weighted imaging and T2
mapping have only been used in cases series and small
feasibility studies. In 32 patients with sarcoidosis,
increased signal in the interventricular septum on T2-
weighted images was more common in patients with
complete heart block than patients with normal conduc-
tion.74 T2 mapping has been used in a study of 28
patients and showed reduced T2 values in regions of
LGE, which the authors speculate may reflect an
inactive phase of the disease.86
The above limitations related to evaluating the
diagnostic accuracy of CMR, similar to the ones for
FDG-PET underscore the importance of evaluating the
prognostic findings provided by various imaging results,
as the ultimate identification of patients who have a
higher risk of adverse events may be most important for
guiding therapy. Finally, as discussed in ‘Approach to
Sarcoidosis Imaging Procedures’ section, with the
exception of a few small reports, focal LGE by CMR
has consistently been linked with adverse clinical
outcome.76,77,87,88
Of equal importance, the absence of LGE in patients
with suspected cardiac sarcoidosis is generally associ-
ated with a favorable prognosis,76 although some studies
have shown conflicting findings.77
In summary, CMR is a multi-parametric imaging
modality that can accurately delineate cardiac morphol-
ogy and function and interrogate tissue characteristics.
CMR is a valuable tool for the diagnosis and risk
assessment of cardiac sarcoidosis. Whether CMR can be
used to assess response to therapy is unclear, as CMR
findings are limited by a relatively low specificity to
distinguish scar from active inflammation. However, the
relatively high sensitivity of the technique contributes to
the exclusion of cardiac sarcoidosis.
COMPUTED TOMOGRAPHY
CT plays a limited role in the evaluation and
management of patients with systemic sarcoidosis.
Although, cardiac CT has no established role for the
diagnosis of cardiac sarcoidosis, coronary CT angiogra-
phy may play an important role in excluding CAD in
individuals with LV dysfunction and regional wall
motion abnormalities.
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IMAGING TO GUIDE BIOPSY
Cardiac involvement is often difficult to diagnose
because endomyocardial biopsy is limited by sampling
error and complication risk cannot be ignored.45,89,90 The
diagnosis of isolated cardiac involvement is therefore
difficult and laboratory abnormalities are non-specific. If
the likelihood of an inflammatory cardiomyopathy
remains high despite a negative endomyocardial biopsy,
pursuing the diagnosis with repeated and image-guided
biopsies of the myocardium or mediastinal lymph nodes
is worthwhile and may markedly improve the detection
rate of cardiac sarcoidosis.91 Biopsy guided by elec-
tromechanical mapping has also been used for the
diagnosis of isolated cardiac sarcoidosis.92 Although
focal myocardial LGE, high T2 signal on CMR, and
increased glucose uptake on cardiac FDG-PET are non-
specific signs of myocardial damage or inflammation, in
patients with histologically proven extracardiac sar-
coidosis, they provide sensitive signs of sarcoid
involvement of the heart.54,82 In patients with biopsy-
proven cardiac sarcoidosis, abnormal LGE and FDG-
PET findings were observed in 94% and 80% of patients,
respectively.91 However, without histopathological ver-
ification, even typical abnormalities on CMR or PET
may not provide a definitive diagnosis and decisions
regarding long-term immunosuppression in such patients
with suspected, but not proven, cardiac sarcoidosis
remains challenging and must be individualized. The
role of hybrid PET/CT and PET/MRI to guide biopsy
remains to be evaluated (see ‘Future Directions’ section).
In summary, abnormal cardiac findings on CMR
and/or FDG-PET are frequent and suggest localized
Figure 4. Example of FDG and myocardial perfusion PET in sarcoidosis: assessing response to
therapy with FDG-PET. A 48-year-old man with mild exertional dyspnea with exercise that
progressed to more severe dyspnea and with lightheadedness and dizziness. His ECG should
complete heart block with ventricular escape rate of 45 bpm, catheterization revealed no coronary
artery disease, and his left ventricular ejection fraction was 52%. A cardiac MRI suggested four
areas of inflammatory/infiltrative processes in the basal septal and anteroseptal regions. A CT scan
of the chest revealed enlarged mediastinal lymph nodes and bilateral pulmonary nodules. An
endomyocardial biopsy showed non-specific mild hypertrophy. A mediastinoscopy with biopsy of a
mediastinal lymph nodes confirmed extensive (confluent) non-necrotizing granulomas consistent
with sarcoidosis. An FDG-PET scan was performed prior to initiation of prednisone therapy. It
revealed multiple foci of inflammation in the left and right ventricular walls (SUVmax 5.7) as well
as in the mediastinum. Oral prednisone 40 mgday-1 was initiated and an ICD was implanted.
Three months after high-dose steroid therapy, a repeat FDG-PET scan showed that myocardial
(SUVmax 1.5) and mediastinal inflammation is substantially decreased (blood pool FDG activity is
noted), but splenic and abdominal lymph node inflammation persisted. No myocardial perfusion
defects were noted suggesting no regions of fibrosis.
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areas of myocardial damage and/or inflammation in
patients with cardiac sarcoidosis. In a clinical setting
suggestive of cardiac sarcoidosis, ‘hot’ mediastinal or
cervical lymph nodes on FDG-PET provide a biopsy
target that may improve the success rate of identifying
sarcoid histopathology. The potential role of image-
guided endomyocardial biopsy to improve the yield for
histopathological diagnosis of cardiac sarcoidosis
requires further evaluation.
IMAGING TO INITIATE AND MONITOR
THERAPY
Immunosuppressive therapy is frequently used to
treat cardiac sarcoidosis. Sarcoidosis experts, using a
Delphi study method, agreed on the treatment of cardiac
sarcoidosis with immunosuppressive therapy for the
following clinical scenarios: LV dysfunction, ventricular
arrhythmias, hypermetabolic activity on cardiac FDG-
PET, presence of conduction defects, LGE on CMR, or
right ventricular dysfunction in the absence of pul-
monary hypertension.93 But, due to high side effect
profile of immunosuppressive drugs, image-guided ini-
tiation and tailoring of therapy are critical.
A multimodality imaging approach may be neces-
sary for the decision making about pacemaker or ICD.10
Per HRS guidelines,10 ICD is indicated, if LVEF remains
\35% after immunosuppressive therapy (Class I) or if
LGE is present in patients with LVEF 35%-49% after
immunosuppression (Class IIb).
Echocardiography and/or CMR features are not
very specific for inflammation. However, they may help
in the assessment of LV remodeling, left as well as right
ventricular function, pulmonary artery hypertension, and
in the follow-up of end stage heart failure from cardiac
sarcoidosis before and after heart transplantation.25 The
Table 5. Summary of studies examining the prognostic value of CMR and FDG-PET in cardiac
sarcoidosis
Study
Number/
type of
patients
Patients
with
abnormal
LGE/PET
N (%)
Median
F/U
(months)
Overall
number
of events
Number of
events in
patients
without LGE/
normal PET Conclusions
Patel
et al82
81 w/
extracardiac
disease
21 (26) 21 8 (5 Death,
2 VT, 1 AVB)
2 (1 Cardiac
death; 1 non-
cardiac death)
(?) CMR associated
with events; more
sensitive than
clinical criteria
Greulich
et al76
155 w/
extracardiac
disease
39 (25) 31 12
(Death/
SCD/ICD Rx)
1 (1 Non-cardiac
death)
(?) CMR is a strong
predictor of
potentially lethal
events
Nagai
et al77
61 w/extracardiac
disease
8 (13) 50 1 (1 AVB) 2 (2 Non-
cardiac death)
Both patients with
and w/out LGE
had low event rates
Nadel
et al95
106 w/
extracardiac
or cardiac
disease
32 (30) 37 (mean) 4 SCD 1 (1 SCD) LGE ? higher rate
of SCD/VT/VF
8 VT/VF
(8 no cardiac
deaths)
ICD in cardiac sarcoidosis
? associated with lower
mortality
Murtagh
et al83
205 w/
extracardiac
disease and
EF[50%
41 (20) 36 (Mean) 12 Death/VT
(8 deaths;
4 VT)
2 (2 Deaths) LGE ? higher rate
of death/VT, even
with preserved EF
Blankstein
et al45
118 w/
extracardiac
disease
37 (31) 18 31 (27 VT and
8 deaths)
4 VT events and 3
deaths, 1 in a
patient who
also had VT
Focal PD and FDG
uptake on cardiac
PET identifies patients
at higher risk of
death or VT
Ahmadian
et al44
34 w/
extracardiac
disease
23 (61) 3 11 VT, AVB,
heart failure
1 Quantification of FDG
uptake in CS by
CMA is an important
tool for prognostication
in patients with known
or suspected cardiac
sarcoidosis
CS, cardiac sarcoidosis, PD, perfusion defects, LGE, late gadolinium enhancement, VT, ventricle tachycardia, VF, ventricle fibrillation, SCD, sudden
cardiac death, AVB, atrio-ventricular block, ICD, implantable cardioverter defibrillators, EF, ejection fraction, CMA, cardiac metabolic activity
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use of echocardiography and CMR (and LGE) to assess
changes in inflammation in response to therapy is
limited.94
Observational studies suggest an important role for
FDG-PET to monitor efficacy of immunosuppressive
therapy.53 Osborne et al examined 23 patients who
underwent serial FDG-PET exams during treatment for
cardiac sarcoidosis. They showed that a quantitative
reduction in the intensity (i.e., SUVmax) or extent (i.e.,
volume of inflammation above a pre-specified SUV
threshold) was associated with improvement in LVEF.59
Although clear response to therapy is seen in some case
(Figure 4), the use of visual analysis to assess serial
changes in response to therapy may be limited partic-
ularly when there is partial response (see ‘Myocardial
perfusion imaging’ section). Quantitative metrics of
SUVmax as well as volume of myocardial pixels with
SUV above a certain threshold, and changes in extent
and severity of myocardial perfusion, may be preferred
to assess response to therapy. Whether steroid induced
glucose metabolic changes influence FDG uptake by the
myocardium is not known. The duration of treatment is
based on clinical response and can be guided by disease
activity on FDG-PET, Figure 6.88 The optimal timing to
repeat FDG-PET imaging is not known. We suggest
repeating FDG-PET approximately 4-6 months after
initiation of therapy.
In summary, in the absence of specific guidelines, in
asymptomatic patients with cardiac sarcoidosis,
echocardiography is useful to follow-up LVEF and to
evaluate for new wall motion abnormalities, wall thin-
ning. A quantitative FDG-PET with MPI may be useful
to monitor progression of scar and inflammation and
assess response to active immunosuppressive therapies.
Prospective randomized clinical trials of imaging guided
management of immunosuppressive therapy are
warranted.
PROGNOSIS
Several groups of investigators have studied the
value of structural and functional myocardial changes of
cardiac sarcoidosis detected on echocardiography,
CMR, and FDG-PET in predicting prognosis (Table 5).
The extent of LV dysfunction and dilatation at baseline
are important predictors of survival.23 Further, a reduced
global longitudinal strain is an independent predictor of
adverse events among patients with suspected cardiac
sarcoidosis.25 The presence of LGE on CMR, including
focal LGE,76 and the extent of LGE (LGE mass C20%
of LV mass), is associated with a higher risk of death or
VT and a lower likelihood of improvement in LV
function.83,99 The prognostic value of other CMR
Figure 5. Non-invasive imaging approach to initial evaluation of patients with suspected cardiac
sarcoidosis. CS, cardiac sarcoidosis, CMR, cardiovascular magnetic resonance imaging, ECG,
electrocardiogram, Echo, echocardiogram, FDG, 18F-fluorodeoxyglucose, ICD, implantable car-
dioverter defibrillator, LGE, late gadolinium enhancement, MPI,myocardial perfusion imaging, Rx,
therapy. Identify coexistent inflammation; FDG-PET/CT may be preferred first test in individuals
with known systemic sarcoidosis where systemic sarcoidosis activity needs to be assessed. *If
clinical suspicion is high or symptoms persist, FDG-PET/CT and MPI may be considered in
patients with normal CMR. Immunosuppressive Rx may be considered taking into account the
amount of inflammation. Patients with ICD are excluded for CMR.
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findings have been less well studied and no reports are
available for T2 weighted CMR. In one study, LVEF
was a weaker prognosticator than LGE.83 Importantly,
patients who do not have any late enhancement had an
extremely low event rate, with very few cardiac events
reported. Therefore, CMR may be used not only to
exclude the presence of cardiac sarcoidosis in the vast
majority of patients with suspected disease, but also to
identify patients who have an excellent prognosis, with a
strong value of LGE. Also, patients with a combination
of (a) increased myocardial inflammation (i.e., focal
uptake of FDG) and (b) resting perfusion defects are at
high risk for death or VT (4-fold increased risk),45
independent of LVEF, clinical criteria, and the presence
of active extracardiac disease.44,45 In addition, the
presence of focal uptake of FDG by the right ventricle
was found to be associated with an extremely high event
rate. Notably, the presence or absence of active extrac-
ardiac sarcoidosis was not associated with adverse
events.
Based on the published studies to date, the event
rate in patients referred for cardiac PET is higher than
those referred for CMR. This difference can be
explained by the fact that patients referred for PET are
more likely to already have an ICD (which is sometimes
a contraindication for CMR) and prior history of VT.
Therefore, this most likely reflects a referral bias based
on the fact that patients referred for PET imaging have
higher degree of disease activity.97,98
In summary, while there is a paucity of data in this
regard, it seems plausible that the findings provided by
echocardiography (which provides an estimate of
myocardial remodeling and function), CMR (which
provides an estimate of the extent of scar), PET imaging
with FDG (which provide an estimate of the overall
magnitude and extent of myocardial inflammation), and
MPI (which provides an estimate of microvascular
dysfunction and/or scar) may be complementary, both
for diagnosing and treating disease, as well as for
providing an estimate of the risk of future adverse
events.
APPROACH TO SARCOIDOSIS IMAGING
PROCEDURES
The approach to cardiac sarcoidosis imaging may
include multiple imaging tests (Figure 5). The main
indications for advanced imaging in cardiac sarcoidosis:
(i) suspected cardiac involvement in patients with
biopsy-proven extracardiac sarcoidosis and symptoms
(unexplained syncope/presyncope/significant palpita-
tions), and/or abnormal ECG and/or inconclusive
echocardiogram10; (ii) suspected relapse in a patient
with a history of cardiac sarcoidosis; (iii) treatment
monitoring in patients diagnosed with cardiac sarcoido-
sis. In addition, advanced imaging may contribute to (iv)
prognostic assessment that may impact on therapeutic
management and follow-up.19,99,100 Radionuclide imag-
ing, particularly FDG-PET with SUV quantitation and in
conjunction with MPI, may be useful to not only detect
myocardial inflammation but also to monitor progres-
sion of scar and inflammation and assess response to
active immunosuppressive therapies (Figure 6).
FUTURE DIRECTIONS
The future of cardiac sarcoidosis imaging relies on
development of novel inflammation specific radiotrac-
ers, hybrid imaging devices, as well as multidisciplinary,
and multiinstitutional collaborations using standardized
imaging methods. Novel somatostatin receptor binding
radiopharmaceuticals such as 68Ga-DOTATOC/TATE/
NOC, radiotracers of inflammation (11C-PBR28), and
18F-FLT (fluorothymidine) as well as novel CMR
contrast agents such as Ferumoxytol (contrast agent
Figure 6. Use of FDG-PET imaging to guide immunosup-
pressive therapy in cardiac sarcoidosis. In cardiac sarcoidosis
patients with positive FDG-PET imaging, repeat FDG-PET
imaging can be repeated to judge treatment response, however,
whether the result of FDG-PET can be used to taper
immunosuppressive therapy is currently unclear and evidence
is lacking to adjust treatment based on imaging. *The optimal
timing of repeat FDG-PET imaging is not well established, but
approximately 4-6 months following treatment initiation is
commonly employed, or when significant changes in therapy
are being considered. FDG, 18F-fluorodeoxyglucose; Rx,
therapy.
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consisting of ultrasmall superparamagnetic particles of
iron oxide that are taken up by macrophages, are under
evaluation (http://www.clinicaltrials.gov). In addition,
novel hybrid imaging systems combining PET and MRI
(PET/MRI camera) provide highly complementary
information on tissue characterization and metabolic
information in one single session.101,102 Due to the lack
of a gold standard for the diagnosis of cardiac sar-
coidosis, the lack of specificity of the imaging findings,
and the potential risk of high-dose immunosuppressive
therapies, sarcoidosis is challenging to diagnose and
manage. A multidisciplinary heart team approach
involving experienced imagers (echocardiography,
CMR, and radionuclide imaging), internal medicine
physicians, cardiologists, heart failure physicians, pul-
monary physicians, electrophysiologists,
rheumatologists, pathologists, and others will be critical
to manage sarcoidosis.
CONCLUSIONS
Sarcoidosis is a complex systemic disease that often
requires multidisciplinary expertise and approach for
diagnosis and management. Detection of cardiac sar-
coidosis is important to prevent life-threatening
arrhythmias and to preserve LV function in affected
individuals. A multi-imaging approach that can identify
disease activity, prognosis, and response to therapy is
needed to improve further the management of patients
with cardiac sarcoidosis. Optimal imaging based on
standardized procedural guidelines for acquisition, inter-
pretation, and quantification is paramount.
SUPPLEMENTARY DATA
Supplementary data are available at Journal of
Nuclear Cardiology online.
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